GlassScriptPhysician profile
James Rutland
NPI 1689678468
$1,866.12
in general payments reported to CMS, 2019-2025
22 companies · $31.75 in 2025
The $31.75 reported for 2025 was less than what a typical provider received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $128 · 2020: $56.12 · 2021: $59.47 · 2022: $585 · 2023: $463 · 2024: $542 · 2025: $31.75.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,037.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,037.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $543.85 | 2019-2024 | Rinvoq, Skyrizi, Mavyret |
| Regeneron Healthcare Solutions, INC. | $295.89 | 2023-2025 | Dupixent |
| United Therapeutics Corporation | $218.27 | 2022-2024 | |
| Nestle Healthcare Nutrition INC. | $103.43 | 2021-2023 | |
| Glaxosmithkline, LLC. | $95.09 | 2024 | Nucala |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $85.17 | 2019-2023 | Xifaxan |
| Janssen Biotech, INC. | $84.49 | 2022-2023 | Simponi, Simponi Aria, Remicade |
| Ironwood Pharmaceuticals, INC | $67.34 | 2022-2023 | Linzess |
| Pfizer INC. | $62.22 | 2019-2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $61.81 | 2019-2022 | |
| Allergan, INC. | $38.45 | 2019-2020 | |
| Vivus LLC | $34.61 | 2022 | |
| Aimmune Therapeutics, INC. | $27.02 | 2024 | |
| Gilead Sciences, INC. | $20.14 | 2024 | |
| Qol Medical, LLC | $19.52 | 2022 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $19.09 | 2024 | Dificid |
| Amgen INC. | $16.67 | 2022 | |
| Phathom Pharmaceuticals, INC. | $16.65 | 2024 | Voquezna |
| Ferring Pharmaceuticals INC. | $15.56 | 2024 | Rebyota |
| Olympus America INC. | $14.53 | 2020 | |
| Boston Scientific Corporation | $13.64 | 2019 | |
| Intercept Pharmaceuticals, INC. | $12.68 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Rutland listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.